Narrative reviewindependent cross-checkabstract checked I-EGG-131 standard review
All current lupus kidney guidelines rely on medicines, including biologics
Comparative Analysis of Lupus Nephritis Guidelines: ACR 2025, EULAR 2025, and Kdigo 2024.
Overview
Xipell M et al.. Nephrol Dial Transplant 2026 · PMID 42101868 · DOI 10.1093/ndt/gfag106
ACR 2025, EULAR 2025 and KDIGO 2024 recommend early combination drug treatment, including biologic drugs, for lupus nephritis.
Does the study support the specific claim? No · Methodological quality: moderate
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Compare lupus nephritis guidelines.
- How was the study done?
Narrative review.
- How many people, animals or samples were studied?
3 guidelines.
- What was actually found?
Convergence on early combination immunotherapy.
- How large was the observed effect?
Not applicable.
- What do the results mean in everyday life?
Lupus with kidney involvement needs medical treatment; diet is not a substitute.
- What are the study's limitations?
Review, not the guidelines themselves.
- What does it say about Elawady's specific claim?
Contradicts replacing biological therapy with egg avoidance.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
It does not test diets.
Scientific in-depth review
1. Full reference
- Authors
- Xipell M et al.
- Journal
- Nephrol Dial Transplant
- Year
- 2026
- Identifier
- PMID 42101868 DOI 10.1093/ndt/gfag106
- Verification
- verified – PubMed efetch 2026-10-26; Crossref works API 2026-10-26
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
not stated in abstract
2. Research question
How do the ACR 2025, EULAR 2025 and KDIGO 2024 lupus nephritis guidelines compare?
3. Study design and population
- Study design
- Narrative review – Narrative comparative review of three current clinical guidelines
- Population
Patients with lupus nephritis (guideline scope)
- Country
International (USA, Europe, global)
- Period
not stated in abstract
- Sample size
3 guidelines
- Inclusion and exclusion criteria
not detailed in abstract
4. Methods and endpoints
- Exposure / intervention
Guideline recommendations
- Comparator
Between guidelines
- Endpoints
Treatment strategy
- Statistical methods
Not applicable
5. Actual results
- Results
All three recent guidelines share a largely common evidence base and shift toward early combination regimens with targeted therapies (belimumab, voclosporin, obinutuzumab), clinical profiling, rapid glucocorticoid minimisation and renoprotective therapy as a central pillar of lupus nephritis care.
- Absolute risks
not reported
- Authors' conclusion
Guidelines converge on early combination immunotherapy and renoprotection, with differences in scope and emphasis.
6. Strengths
- Covers the three newest guidelines (2024-2025)
7. Weaknesses
- Narrative review; guidelines themselves not fetched
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- low
- Rationale
Secondary summary of guidelines.
9. Assessment of the statistical interpretation
Not applicable.
10. Relevance to the specific claim
Confirms that current international standards for lupus with kidney involvement rely on early immunosuppressive and biological therapy; no guideline lists dietary egg avoidance as a treatment.
11. Independent contrary findings
None.
12. Transferability to Germany and Europe
Directly applicable; Egyptian practice follows international guidelines (not verified).
13. Overall methodological judgement
Up-to-date confirmation that the claim's replacement of biological treatment by egg avoidance contradicts all current guidelines.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | moderate |
| Risk of bias | low |
| Precision of results | not applicable |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Egyptian rheumatology guidance not fetched.